BPC-157 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

BPC-157

Also known as: Body Protection Compound 157, BPC 157, Body Protective Compound 157, Stable Gastric Pentadecapeptide BPC 157, GEPPPGKPADDAGLV

Synthetic pentadecapeptide / gastric cytoprotective peptide

Not FDA-approvedLast updated: November 11, 2026Based on 10 peer-reviewed studies

What it is

BPC-157 is a peptide people use to speed up recovery from soft-tissue injuries like tendon, ligament, and muscle damage. It's also used for gut inflammation and ulcer healing. Not FDA-approved; most research is in animals, with a few small human studies.

The scientific side

BPC-157 is described as a synthetic pentadecapeptide derived from a human gastric protein fragment with reported cytoprotective and regenerative properties. It activates several overlapping pathways including VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization; it also engages ERK1/2 signaling and exerts anti-inflammatory effects. It enhances growth hormone receptor expression and pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines. In wound healing, it acts by resolving vessel constriction, stabilizing platelet plugs, and counteracting arterial and venous thrombosis, and it rapidly increases various gene expression in rat excision skin wounds. In ocular models, it is described as activating collateral pathways to counteract occlusion syndromes and normalize intraocular pressure. It is reported to be stable in gastric juice and to demonstrate activity via oral, parenteral, and topical routes. It is metabolized in the liver, with a half-life of less than 30 minutes, and is cleared by the kidneys.

Class: Synthetic pentadecapeptide / gastric cytoprotective peptide

Not FDA-approvedLow researchDigestiveBonesSynthetic pentadecapeptide (gastric-derived)

At a glance

What it isA 15-amino-acid synthetic peptide (GEPPPGKPADDAGLV) based on a protein found in human gastric juice.
FDA statusNot approved for any use. An FDA advisory committee voted 8-6 in July 2026 to let compounding pharmacies make it; that vote is a recommendation only.
Used forTendon, ligament, muscle and gut healing, mostly on the strength of animal studies.
Human evidenceThree small uncontrolled pilot studies (2, 12 and 16 people). No completed, published randomized trial.
Half-lifeUnder 30 minutes in rats and dogs. No human data.
Banned in sportYes. WADA lists it by name under S0 Non-Approved Substances, prohibited at all times.
Common formsInjection under the skin or into muscle; oral capsules. Sold mostly as an unregulated "research chemical".

What is BPC-157?

BPC-157 ("Body Protection Compound 157") is a synthetic peptide of 15 amino acids, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a fragment of a larger protective protein that its discoverers isolated from human gastric juice. Unlike many peptides it stays stable in stomach acid, which is why it is studied by mouth as well as by injection.

It is best known for tendon, ligament and muscle recovery, and for gut problems like ulcers and inflammatory bowel disease. It is often stacked with TB-500. Almost all of that reputation comes from rodent studies.

Sources: [1] [2]

How does it work?

In animal and cell studies, BPC-157 appears to act on blood-vessel growth and repair. It activates the VEGFR2 receptor and the Akt-eNOS nitric oxide pathway, promotes new blood vessels (angiogenesis) and fibroblast activity, and engages ERK1/2 signaling. These effects are proposed to matter most in tissues with a poor blood supply, like tendons. Reviews also describe increased growth hormone receptor expression and lower inflammatory cytokines.

None of these mechanisms has been confirmed in humans. The pharmacokinetic figures below come from rats and dogs.

Pharmacokinetics

Half-lifeUnder 30 minutes in rats and dogs, IV and intramuscular (no human data)
MetabolismRapidly broken down into small peptide fragments and then single amino acids (animal data)
ClearanceExcreted mainly in urine and bile (animal data)
RouteStudied by injection (IV, intramuscular, subcutaneous) and by mouth; intramuscular bioavailability about 14-19% in rats and 45-51% in dogs

Sources: [3] [4] [5]

Is it FDA-approved?

No. BPC-157 has never been approved by the FDA for any use, and no company has completed the trials an approval would need.

What changed in 2026 is compounding, not approval. In April 2026, FDA moved BPC-157 off its list of compounding substances with significant safety risks ("Category 2") after the nominators withdrew it. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8-6, with 1 abstention, to recommend adding it to the list of substances compounding pharmacies may use. The vote is not binding: FDA would still have to accept it and complete proposed and final rulemaking. FDA's own reviewers had recommended against it, citing short, underpowered studies.

  • WADA: S0 Non-Approved Substances (named in the 2026 Prohibited List; prohibited at all times)

Sources: [6] [7] [8]

History

The idea dates to 1975, when Predrag Sikiric, then a medical student in Zagreb, reasoned that the stomach must make its own anti-stress compounds. His team spent years collecting gastric juice from clinics, emergency rooms and pig slaughterhouses. Sikiric says that in 1989 they found a protective protein, and from it a 15-amino-acid fragment he named BPC 157.

In 1993 Sikiric signed a contract with the Croatian drug maker PLIVA, which developed the peptide as PL 14736 alongside university researchers and the American company Parke-Davis. In the early 2000s PLIVA ran two early-stage trials in ulcerative colitis. The full results were never published; a short 2005 write-up reported a positive effect in the second trial that did not reach statistical significance.

In 2006 PLIVA's research institute was sold to GlaxoSmithKline, which dropped the project. At the end of 2009 the rights returned to Sikiric, whose group has continued mostly rodent research. Around 2010, bodybuilders on online forums began sourcing BPC-157 from suppliers in China, and a grey market grew from there.

Sources: [9] [2]

Regulatory timeline

  1. September 29, 2023FDA places BPC-157 in Category 2 (503A): substances that may present significant safety risks in compounding, citing immunogenicity, impurity concerns and limited safety data. Source
  2. April 2026FDA lists BPC-157 under "nominated but withdrawn": the nominators withdrew it, so it is no longer in Category 2. FDA's page was updated April 22, 2026. Source
  3. July 23, 2026FDA's Pharmacy Compounding Advisory Committee votes 8-6, with 1 abstention, to recommend BPC-157 for the 503A bulks list. The vote is a non-binding recommendation. Source
  4. As of October 2026Still not FDA-approved for any use. Compounding would still require FDA to accept the recommendation and complete rulemaking. Source

Side effects

There is no reliable human side-effect data. The three published human pilot studies (2, 12 and 16 people) reported no adverse events, but they had no control groups and were far too small to detect uncommon problems. The only registered trial, an oral phase 1 study in 42 healthy volunteers (NCT02637284), never posted results.

Users online have described side effects including whole-body itching, intense anxiety and anhedonia (loss of pleasure). These are anecdotes, not evidence that BPC-157 caused them. Because the peptide promotes blood-vessel growth, reviewers have raised a theoretical concern about tumor growth; no study has shown it causes or speeds up cancer, and none has tested long-term use. Grey-market vials add their own risks: contamination, wrong dose or a different substance.

Who should not use it

  • No established contraindications: BPC-157 has never been through the trials that would define them.
  • Competitive athletes: prohibited at all times under WADA S0.
  • Pregnancy, breastfeeding, and people with active or past cancer were not studied; the theoretical angiogenesis concern makes caution reasonable.

No controlled human trial has published adverse-event data. NCT02637284 (oral, 42 planned participants, sponsor PharmaCotherapia) has no posted results and its ClinicalTrials.gov status is "Unknown".

Sources: [10] [11] [12] [13] [14] [15]

What does the research show?

A 2025 systematic review in orthopaedic sports medicine found 36 eligible studies published between 1993 and 2024: 35 preclinical and 1 clinical. In animals, BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries. The review found no clinical safety data.

The human studies are small and uncontrolled. In a retrospective chart review of knee injections, 14 of 16 people reported relief from knee pain. In a pilot study of 12 women with interstitial cystitis, bladder-wall injections during cystoscopy resolved symptoms in 10. In a 2-person safety pilot, IV infusions of 10 mg and 20 mg caused no measurable changes in heart, liver, kidney, thyroid or glucose tests. A 2025 narrative review concluded BPC-157 "should be considered investigational, and its use approached with caution."

Studied for

  • Tendon, ligament and muscle injury (animal studies)
  • Bone healing (animal studies)
  • Ulcerative colitis (two unpublished PLIVA trials, early 2000s)
  • Knee pain (16-person retrospective case series)
  • Interstitial cystitis (12-person pilot study)

Sources: [4] [12] [11] [10] [3]

FAQ

Is BPC-157 FDA-approved?

No, not for any use. The July 2026 advisory committee vote was about compounding, not approval, and it was a non-binding recommendation.

Sources: [7] [6]

Can a compounding pharmacy make BPC-157 now?

Not yet under the normal 503A route. BPC-157 left Category 2 in April 2026 and the advisory committee recommended it in July 2026, but FDA still has to accept that recommendation and finish proposed and final rulemaking before it is added to the bulks list.

Sources: [8] [6]

Is BPC-157 safe?

Nobody knows. The published human data are three uncontrolled pilot studies totalling 30 people, which reported no adverse events but cannot establish safety. There are no long-term human data.

Sources: [3] [4]

Oral or injection: which works better?

There is no human comparison. BPC-157 is stable in gastric juice and works by mouth in animal studies, but the only oral human trial never published results. In rats and dogs, intramuscular bioavailability was about 14-19% and 45-51% respectively.

Sources: [13] [5]

Is BPC-157 banned in sports?

Yes. The WADA Prohibited List names BPC-157 under S0 Non-Approved Substances, which is prohibited at all times, in and out of competition. Some published reviews say otherwise; the current list is the authority.

Sources: [16] [17]

Can BPC-157 cause cancer?

No study has shown that it causes or speeds up cancer. Because it promotes blood-vessel growth, one review team calls this "a plausible tumor-promoting hazard". Sikiric's group counters that BPC-157 controls vessel growth rather than driving it and reports anti-tumor effects in animal and cell studies. Neither side has long-term tumor studies in animals or people.

Sources: [15] [18]

How long does BPC-157 stay in the body?

In rats and dogs, its half-life was under 30 minutes and it was broken down into amino acids. There are no human half-life measurements.

Sources: [5]

Does it need lab monitoring?

There is a separate lab-monitoring guide for BPC-157, linked in the sidebar, covering the baseline, mid-cycle and post-cycle tests people commonly run.

Citations

  1. Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel) 2025. PMID 40005999
  2. Sikiric P, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem 2012. PMID 22300085
  3. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025. PMID 40789979
  4. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025. PMID 40756949
  5. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol 2022. PMID 36588717
  6. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  7. Todd S, Lawrence L. FDA panel backs compounded BPC-157, KPV peptides in win for RFK Jr. STAT, July 23, 2026. statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv
  8. Steinzor P. FDA panel backs 6 peptides for compounding. AJMC, July 31, 2026. ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
  9. Talpos S (Undark). BPC-157 peptide: a secretive Croatian researcher's 50-year quest. STAT, June 1, 2026. statnews.com/2026/06/01/bpc-157-researcher-predrag-sikiric-addesses-skeptics-questions
  10. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025. PMID 40131143
  11. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med 2024. PMID 39325560
  12. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021. PMID 34324435
  13. NCT02637284: Phase I pilot study of PCO-02 (oral BPC-157) in healthy volunteers. clinicaltrials.gov/study/NCT02637284
  14. Talpos S (Undark). BPC-157: the peptide with big claims and scant evidence. STAT, February 3, 2026. statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions
  15. Józwiak M, et al. Reply to Sikiric et al. Pharmaceuticals (Basel) 2025. PMID 41155566
  16. World Anti-Doping Agency: Prohibited List 2026, section S0 (Non-Approved Substances). wada-ama.org/en/prohibited-list
  17. USADA: BPC-157: experimental peptide creates risk for athletes. usada.org/spirit-of-sport/bpc-157-peptide-prohibited
  18. Sikiric P, et al. BPC 157 therapy: targeting angiogenesis and nitric oxide's cytotoxic and damaging actions. Pharmaceuticals (Basel) 2025. PMID 41155565

Sources

Administration & storage

Administration
Intravesical injection (PMID: 39325560)Intraperitoneal injection (PMID: 36551977)Intramuscular injection — preclinical (PMID: 42198317)Intravenous — human pharmacokinetic pilot (PMID: 42198317)Intraarticular injection — retrospective clinical study (PMID: 40756949)Oral/drinking water — animal studies (PMID: 36551977)Topical — animal studies (PMID: 36551977)
Storage
No storage conditions for BPC-157 formulations are described in the reviewed abstracts.
Cautions
No pharmaceutical-grade formulation has been developed or validated; the peptide lacks BCS classification, permeability characterization, and formal excipient compatibility studies.,Available human clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations.,Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety profile.,Human pharmacokinetic data are critically undercharacterized; a sub-30-min plasma half-life has been confirmed only in a two-subject preliminary human pilot.,Sterile technique is essential for any injectable preparation; compounding pharmacy sourcing introduces additional quality variability.

Legal & regulatory status

US FDA

Not approved by the US Food and Drug Administration for any therapeutic indication (PMID: 39325560, PMID: 40005999, PMID: 42198317). No completed Phase II clinical trial as of the reviewed literature.

WADA

Prohibited at all times under WADA S0 (non-approved substances), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026.

Health Canada

Not stated in reviewed literature — requires manual verification